Multi-Ancestry Transcriptome-Wide Association Studies of Cognitive Function, White Matter Hyperintensity, and Alzheimer’s Disease
Genetic variants increase the risk of neurocognitive disorders in later life, including vascular dementia (VaD) and Alzheimer's disease (AD), but the precise relationships between genetic risk factors and underlying disease etiologies are not well understood. Transcriptome-wide association studies (TWASs) can be leveraged to better characterize the genes and biological pathways underlying genetic influences on disease. To date, almost all existing TWASs on VaD and AD have been conducted using expression studies from individuals of a single genetic ancestry, primarily European. Using the joint likelihood-based inference framework in Multi-ancEstry TRanscriptOme-wide analysis (METRO), we leveraged gene expression data from European ancestry (EA) and African ancestry (AA) samples to identify genes associated with general cognitive function, white matter hyperintensity (WMH), and AD. Regions were fine-mapped using Fine-mapping Of CaUsal gene Sets (FOCUS). We identified 266, 23, 69, and 2 genes associated with general cognitive function, WMH, AD (using EA GWAS summary statistics), and AD (using AA GWAS), respectively (Bonferroni-corrected alpha = <i>p</i> < 2.9 × 10<sup>-6</sup>), some of which had been previously identified. Enrichment analysis showed that many of the identified genes were in pathways related to innate immunity, vascular dysfunction, and neuroinflammation. Further, the downregulation of <i>ICA1L</i> was associated with a higher WMH and with AD, indicating its potential contribution to overlapping AD and VaD neuropathology. To our knowledge, our study is the first TWAS on cognitive function and neurocognitive disorders that used expression mapping studies for multiple ancestries. This work may expand the benefits of TWASs beyond a single ancestry group and help to identify gene targets for pharmaceuticals or preventative treatments for dementia.
Authors
- Lulu Shang (ORCID: https://orcid.org/0000-0002-2480-3065)
- Xiang Zhou (ORCID: https://orcid.org/0000-0002-4331-7599)
- Scott M. Ratliff (ORCID: https://orcid.org/0000-0002-6109-662X)
- Jennifer A. Smith (ORCID: https://orcid.org/0000-0002-3575-5468)
- Dima Chaar (ORCID: https://orcid.org/0000-0001-6755-0179)
- Thomas H. Mosley (ORCID: https://orcid.org/0000-0003-3343-1352)
- Zheng Li (ORCID: https://orcid.org/0000-0001-5826-1316)
- Wei Zhao (ORCID: https://orcid.org/0000-0002-4032-5745)
- Sharon L. R. Kardia
Institutions
- The University of Texas MD Anderson Cancer Center (US)
- University of Michigan (US)
- University of Mississippi Medical Center (US)
Publication Details
- Journal
- International Journal of Molecular Sciences
- Published
- 2025-03-09
- DOI
- https://doi.org/10.3390/ijms26062443
- Citations
- 1
- Primary Topic
- Alzheimer's disease research and treatments
- Type
- article
- Field-Weighted Citation Impact
- 1.16
Funders
- National Heart, Lung, and Blood Institute
- National Institute of Neurological Disorders and Stroke